Usa covid-19 testing Ebola prevention Usa

FDA authorises Emory University to trial antiviral for Covid-19

Reading now: 530
www.pharmaceutical-technology.com

Emory University subsidiary DRIVE has received the US Food and Drug Administration (FDA) approval for its investigational new drug application of antiviral compound EIDD-2801 to treat Covid-19.

The approval allows human clinical trials by Ridgeback Biotherapeutics in the US. Ridgeback Biotherapeutics exclusively licensed the compound.

Discovered and developed by the university, EIDD-2801 is an orally available compound that works by preventing the replication of SARS-CoV-2.

In animal models, the drug candidate demonstrated activity against SARS-CoV and MERS-CoV. EIDD-2801 is also capable of activity against several diseases, including Ebola, influenza, chikungunya and equine encephalitis.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA